129 related articles for article (PubMed ID: 9934481)
1. Tricyclic ureas: a new class of HIV-1 protease inhibitors.
Han W; Pelletier JC; Hodge CN
Bioorg Med Chem Lett; 1998 Dec; 8(24):3615-20. PubMed ID: 9934481
[TBL] [Abstract][Full Text] [Related]
2. Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents.
Patel M; Rodgers JD; McHugh RJ; Johnson BL; Cordova BC; Klabe RM; Bacheler LT; Erickson-Viitanen S; Ko SS
Bioorg Med Chem Lett; 1999 Nov; 9(22):3217-20. PubMed ID: 10576691
[TBL] [Abstract][Full Text] [Related]
3. HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
Wilkerson WW; Akamike E; Cheatham WW; Hollis AY; Collins RD; DeLucca I; Lam PY; Ru Y
J Med Chem; 1996 Oct; 39(21):4299-312. PubMed ID: 8863807
[TBL] [Abstract][Full Text] [Related]
4. Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups.
Rodgers JD; Johnson BL; Wang H; Erickson-Viitanen S; Klabe RM; Bacheler L; Cordova BC; Chang CH
Bioorg Med Chem Lett; 1998 Apr; 8(7):715-20. PubMed ID: 9871528
[TBL] [Abstract][Full Text] [Related]
5. [Current status of HIV protease inhibitors].
Yang QG; He XC; Bai DL
Yao Xue Xue Bao; 2005 May; 40(5):389-94. PubMed ID: 16220778
[No Abstract] [Full Text] [Related]
6. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
Frecer V; Burello E; Miertus S
Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
[TBL] [Abstract][Full Text] [Related]
7. The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors.
Patel M; Kaltenbach RF; Nugiel DA; McHugh RJ; Jadhav PK; Bacheler LT; Cordova BC; Klabe RM; Erickson-Viitanen S; Garber S; Reid C; Seitz SP
Bioorg Med Chem Lett; 1998 May; 8(9):1077-82. PubMed ID: 9871711
[TBL] [Abstract][Full Text] [Related]
8. Non-peptidic HIV protease inhibitors.
Chrusciel RA; Strohbach JW
Curr Top Med Chem; 2004; 4(10):1097-114. PubMed ID: 15193141
[TBL] [Abstract][Full Text] [Related]
9. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
[TBL] [Abstract][Full Text] [Related]
10. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
Debnath AK
J Med Chem; 1999 Jan; 42(2):249-59. PubMed ID: 9925730
[TBL] [Abstract][Full Text] [Related]
11. Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
Rodgers JD; Lam PY; Johnson BL; Wang H; Li R; Ru Y; Ko SS; Seitz SP; Trainor GL; Anderson PS; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Wright MR; Chang CH; Erickson-Viitanen S
Chem Biol; 1998 Oct; 5(10):597-608. PubMed ID: 9818151
[TBL] [Abstract][Full Text] [Related]
12. The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.
Patel M; Bacheler LT; Rayner MM; Cordova BC; Klabe RM; Erickson-Viitanen S; Seitz SP
Bioorg Med Chem Lett; 1998 Apr; 8(7):823-8. PubMed ID: 9871548
[TBL] [Abstract][Full Text] [Related]
13. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
[TBL] [Abstract][Full Text] [Related]
14. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.
Hultén J; Bonham NM; Nillroth U; Hansson T; Zuccarello G; Bouzide A; Aqvist J; Classon B; Danielson UH; Karlén A; Kvarnström I; Samuelsson B; Hallberg A
J Med Chem; 1997 Mar; 40(6):885-97. PubMed ID: 9083477
[TBL] [Abstract][Full Text] [Related]
15. Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cage dimeric N-benzyl 4-(4-methoxyphenyl)-1,4-dihydropyridine as representative of a novel class of HIV-1 protease inhibitors: a molecular modeling study.
Hilgeroth A; Fleischer R; Wiese M; Heinemann FW
J Comput Aided Mol Des; 1999 May; 13(3):233-42. PubMed ID: 10216831
[TBL] [Abstract][Full Text] [Related]
16. Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
De Lucca GV; Kim UT; Liang J; Cordova B; Klabe RM; Garber S; Bacheler LT; Lam GN; Wright MR; Logue KA; Erickson-Viitanen S; Ko SS; Trainor GL
J Med Chem; 1998 Jun; 41(13):2411-23. PubMed ID: 9632373
[TBL] [Abstract][Full Text] [Related]
17. Molecular recognition of cyclic urea HIV-1 protease inhibitors.
Ala PJ; DeLoskey RJ; Huston EE; Jadhav PK; Lam PY; Eyermann CJ; Hodge CN; Schadt MC; Lewandowski FA; Weber PC; McCabe DD; Duke JL; Chang CH
J Biol Chem; 1998 May; 273(20):12325-31. PubMed ID: 9575185
[TBL] [Abstract][Full Text] [Related]
18. Six-membered cyclic ureas as HIV-1 protease inhibitors: a QSAR study based on CODESSA PRO approach. Quantitative structure-activity relationships.
Katritzky AR; Oliferenko A; Lomaka A; Karelson M
Bioorg Med Chem Lett; 2002 Dec; 12(23):3453-7. PubMed ID: 12419382
[TBL] [Abstract][Full Text] [Related]
19. Quantitative structure-activity relationship studies on cyclic urea-based HIV protease inhibitors.
Gupta SP; Babu MS; Garg R; Sowmya S
J Enzyme Inhib; 1998 Sep; 13(6):399-407. PubMed ID: 9825304
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel conformationally restricted HIV protease inhibitors.
Salituro FG; Baker CT; Court JJ; Deininger DD; Kim EE; Li B; Novak PM; Rao BG; Pazhanisamy S; Porter MD; Schairer WC; Tung RD
Bioorg Med Chem Lett; 1998 Dec; 8(24):3637-42. PubMed ID: 9934485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
